- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
Détention brevets de la classe C07K 14/535
Brevets de cette classe: 673
Historique des publications depuis 10 ans
|
59
|
50
|
63
|
49
|
54
|
58
|
45
|
69
|
40
|
22
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Modernatx, Inc. | 1260 |
60 |
| Institute for Research in Biomedicine (IRB) | 40 |
16 |
| Yale University | 2363 |
16 |
| Regeneron Pharmaceuticals, Inc. | 4233 |
15 |
| Amgen Inc. | 4055 |
14 |
| Lipoxen Technologies Limited | 48 |
13 |
| Emory University | 1622 |
12 |
| Replimune Limited | 42 |
12 |
| Partner Therapeutics, Inc. | 26 |
12 |
| Children's Healthcare of Atlanta, Inc. | 243 |
11 |
| Elanco US Inc. | 719 |
11 |
| Octapharma AG | 206 |
8 |
| Ubiprotein, Corp. | 11 |
8 |
| Spectrum Pharmaceuticals, Inc. | 75 |
7 |
| Gradalis, Inc. | 50 |
6 |
| IBC Pharmaceuticals, Inc. | 92 |
6 |
| Ningbo Innovative Mechanism Bioscience LLC | 7 |
6 |
| Ambrx, Inc. | 181 |
5 |
| Hanmi Pharm. Co., Ltd. | 569 |
5 |
| The Jackson Laboratory | 337 |
5 |
| Autres propriétaires | 425 |